Global Nanopharmaceuticals Market to Surpass US$ 168.91 Billion by 2026

SEATTLE–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24CMI&src=ctag” target=”_blank”gt;$CMIlt;/agt; lt;a href=”https://twitter.com/hashtag/Liposomes?src=hash” target=”_blank”gt;#Liposomeslt;/agt;–According to Coherent Market Insights, the global nanopharmaceuticals
market was valued at US$ 28,434.3 million in 2017, and is projected to
exhibit a CAGR of 22.1% over the forecast period (2018 – 2026).

Key Trends and Analysis of the Nanopharmaceuticals Market:

Various advantages of nanopharmaceuticals over other medicines such as
faster drug delivery and higher efficiency, increase in research and
development activities for discovery of new products for precision
medicine, cardiovascular, and other diseases, technological advancements
in regenerative medicine, and high prevalence of neurological disorders
and cancer are some of the factors that will increase growth of the
nanopharmaceuticals market.

Ask for a Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/2485

Market players are focused on R&D activities for novel materials for
treatment of cancer and other diseases. Moreover, key players in the
nanopharmaceuticals market are committed to offering new and improved
products in order to address critical unmet needs of patients. For
example, in August 2017, Jazz Pharmaceuticals received FDA approval for
Vyxeos, used for the treatment of acute myeloid leukemia.

Furthermore, key players operating in the market are focused on adopting
various business strategies such as acquisition strategies in order to
gain access to innovative products and expand its product offerings in
the potential market. For instance, in March 2018, Celgene Corporation
acquired Juno Therapeutics, Inc., developer of chimeric antigen
receptor. This acquisition will support Celgene to expand its product
offering and increase its operational capabilities.

However, need for improved characterization, lack of regulatory
guidelines, and toxicity issues are expected to hinder the market
growth. As per the P&T Community Journal, Volume 42, December 2017, Food
and Drug Administration (FDA) issued four guidance documents for
industry regarding the use of nanotechnology in FDA-regulated products,
which include nano drugs in June 2014.

To know the latest trends and insights prevalent in this market,
click the link below:

https://www.coherentmarketinsights.com/market-insight/nanopharmaceuticals-market-2485

Key Market Takeaways:

  • The nanopharmaceuticals market is expected to exhibit a CAGR of 22.1%
    during the forecast period (2018 – 2026). This growth is attributed to
    increasing incidences of cardiovascular diseases, cancer, and
    infectious diseases, and advantages of nanopharmaceuticals over
    macroscopic level of medicines. According to the World Health
    Organization (WHO) Factsheet November 2016, estimated around 16% of
    all deaths of children below 5 years in 2015 were due to Pneumonia.
  • Market growth is attributed to rising approvals and launches of novel
    products for treatment in neurological disorders. For instance, in
    August 2009, Janssen Pharmaceuticals, Inc. received U.S. Food and Drug
    Administration (FDA) approval for Invega Sustenna used in treatment of
    schizophrenia in adults.
  • Key players in the market are focused on adopting mergers and
    acquisitions strategies to enhance its product portfolio, which in
    turn is expected to propel the market growth over the forecast period.
    For instance, in 2017, Gilead Sciences acquired Kite Pharma.
  • Key players operating in the global nanopharmaceuticals market
    include, Abbott, GlaxoSmithKline plc., Eli Lilly and Company,
    Astrazeneca plc., Novavax, Inc., Stryker Corporation, OSI
    Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi
    Tanabe Pharma Corporation, Kaken Pharmaceutical, Selecta Biosciences,
    Par Pharmaceutical, Cerulean Pharma Inc., Navidea Biopharmaceuticals,
    Inc., AbbVie Inc., AMAG Pharmaceuticals, Amgen Inc., Astellas Pharma
    Inc., Celgene Corporation, Gilead Sciences, Inc., JOHNSON & JOHNSON,
    Merck & Co., Inc., Novartis AG, Pfizer, Inc., Hoffmann-La Roche AG,
    Sanofi S.A, Shire Plc., and Teva Pharmaceuticals Industries Limited

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting
firm offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.

Contacts

Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle,
WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

error: Content is protected !!